Skip to main navigation

- Landos - Corp Menu

About Us
- Our Company
- Contact Us
Product Candidates
Science
Investors/Media
Careers
- Why Landos?
- Open Positions

Press Releases

Year

5/25/21

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference

5/19/21

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

5/17/21

Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates

5/17/21

Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets

5/6/21

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease

4/29/21

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

4/26/21

Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting

4/13/21

Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

4/6/21

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

3/4/21

Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investors/Media

Investors/Media

Investor Relations

Investor/Media Home
Press Releases
Events & Presentations
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Investors/Media FAQs

- Landos - Investor Tools

Print Page
RSS Feeds
Email Alerts

Contact

Investor Contact

Michael K. Levitan
Solebury Trout
646-378-2920
mlevitan@soleburytrout.com

Media Contact

Hannah Gendel
Solebury Trout
646-378-2943
hgendel@soleburytrout.com

Landos Biopharma, Inc.
1800 Kraft Drive, Suite 216
Blacksburg, VA 24060

info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

Site Map
Terms of Use
Privacy Policy

©2021 Landos Biopharma All Rights Reserved.